Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2025)

Top diagnostic & research stocks in 2025 ranked by overall Due Diligence Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

According to Due Diligence Score, the 3 best diagnostic & research stocks to buy right now are:

Icon (NASDAQ:ICLR) is the top diagnostic & research stock with a Due Diligence Score of 57, which is 33 points higher than the diagnostic & research industry average of 24. It passed 18 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock lose -20.07% over the past year, overperforming other diagnostic & research stocks by 7 percentage points.

Icon has an average 1 year price target of $278.70, an upside of 40.68% from Icon's current stock price of $198.11.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Icon, 60% have issued a Strong Buy rating, 30% have issued a Buy, 10% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Medpace Holdings (NASDAQ:MEDP) is the second best diagnostic & research stock with a Due Diligence Score of 50, which is 26 points higher than the diagnostic & research industry average of 24. It passed 17 out of 33 due diligence checks and has strong fundamentals. Medpace Holdings has seen its stock return 18.42% over the past year, overperforming other diagnostic & research stocks by 45 percentage points.

Medpace Holdings has an average 1 year price target of $369.43, an upside of 9.51% from Medpace Holdings's current stock price of $337.35.

Medpace Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Medpace Holdings, 28.57% have issued a Strong Buy rating, 0% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Quest Diagnostics (NYSE:DGX) is the third best diagnostic & research stock with a Due Diligence Score of 46, which is 22 points higher than the diagnostic & research industry average of 24. It passed 16 out of 38 due diligence checks and has strong fundamentals. Quest Diagnostics has seen its stock return 13.07% over the past year, overperforming other diagnostic & research stocks by 40 percentage points.

Quest Diagnostics has an average 1 year price target of $173.58, an upside of 14.8% from Quest Diagnostics's current stock price of $151.20.

Quest Diagnostics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Quest Diagnostics, 33.33% have issued a Strong Buy rating, 25% have issued a Buy, 41.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 8 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Enzo Biochem (NYSE:ENZ) has an annual dividend yield of 15.27%, which is 13 percentage points higher than the diagnostic & research industry average of 2.68%.

Enzo Biochem's dividend payout ratio of -22.2% indicates that its high dividend yield might not be sustainable for the long-term.

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.78%, which is the same as the diagnostic & research industry average of 2.68%.

Qiagen Nv's dividend payout ratio of 348.8% indicates that its dividend yield might not be sustainable for the long-term.

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.49%, which is -1 percentage points lower than the diagnostic & research industry average of 2.68%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 39.4% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were down -0.64% in the last day, and up 0.93% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Icon has a valuation score of 86, which is 72 points higher than the diagnostic & research industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Icon's stock has dropped -20.07% in the past year. It has overperformed other stocks in the diagnostic & research industry by 7 percentage points.

Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 57 points higher than the diagnostic & research industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -19.89% in the past year. It has overperformed other stocks in the diagnostic & research industry by 7 percentage points.

Charles River Laboratories International (NYSE:CRL) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Charles River Laboratories International has a valuation score of 57, which is 43 points higher than the diagnostic & research industry average of 14. It passed 4 out of 7 valuation due diligence checks.

Charles River Laboratories International's stock has dropped -19.66% in the past year. It has overperformed other stocks in the diagnostic & research industry by 7 percentage points.